Dr. Guangjing Zhu was born in China in 1983. He received his M.D. degree in 2006 and his Ph.D. degree in 2012 from Xi’an Jiaotong University School of Medicine. He came to Johns Hopkins University School of Medicine as an exchanged Ph.D. candidate in 2008 and continued his research in Hopkins after graduation. His current research focus is on translational studies of prostate cancer, including biomarkers development, nuclear morphometry and their uses in the early diagnosis and effective management of Active Surveillance patients and late stage prostate cancer patients; his research area also includes multi-drug resistance mechanisms of chemotherapy and how to reduce such resistance in the treatment of prostate cancer and other cancers. Apart from his clinical background, he has a broad background including epigenetics and whole genome sequencing (ChIP-Seq, RNA-Seq, etc.), embryonic stem cell and DNA methylation, obesity, diabetes and central nervous system regulation of metabolism, etc. He is striving to use the state of the art techniques to tackle critical diseases in medical research. Dr. Zhu is currently serving as Editor of Translational Biomedicine, Section Editor of SM Journal of Biology, Editorial Board Member of Journal of Gastroenterology and Hepatology Research and SM journal of Diabetes and Metabolism; He is also an invited reviewer for 8 peer-reviewed journals including Oncotarget, PLos One, World Journal of Urology, Journal of Cellular Biochemistry, etc.

Prostate cancer, biomarker, drug resistance, nuclear morphometry; epigenetics, whole genome sequencing; obesity and diabetes.